BioSpace News Archive

Nicox SA, an international ophthalmology company, announced the financial and operating results for Nicox and its subsidiaries for the year ended December 31, 2022, as approved by the Board of Directors on March 17, 2023, and updated key future milestones.

The Chinese National Medical Products Administration has approved the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that CEO Ryan Davies spoke with oncology researcher and biotech trailblazer Dr. David Bearss on his experience with cancer therapeutics and advice for young biotechnology companies.